Kornimate/medical-research-clean huggingface dataset:
assessing the clinical outcomes of dapagliflozin versus acetazolamide in patients with acute heart failure

Conditions: Acute Heart Failure

Summary: this study investigates the comparative clinical outcomes of dapagliflozin, an sglt-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (ahf). the trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. this research seeks to provide evidence for incorporating these drugs into ahf management, with the potential to improve clinical outcomes.


Eligibility criteria:
inclusion criteria: 1. adults aged 18 years or older who are hospitalized for hypervolemic ahf, with evidence of congestion defined as either: * 2 of the following signs or symptoms: peripheral edema, ascites, jugular venous pressure \> 10mmhg, orthopnea, paroxysmal nocturnal dyspnea, 5-pound weight gain, or signs of congestion on chest x-ray or lung ultrasound. or * if pulmonary artery catheterization is available, a pulmonary capillary wedge pressure greater than 19 mmhg plus a systemic physical exam finding of hypervolemia from the list above. 2. randomized within 24 hours of hospitalization for ahf. 3. planned use of iv loop diuretic therapy during current hospitalization 4. estimated glomerular filtration rate (egfr) of at least 30 ml/min/1.73m2 by the mdrd equation. exclusion criteria: 1. unable to follow instructions. 2. treated with any proximal tubular diuretics. 3. systolic blood pressure of less than 90 mm hg. 4. an estimated glomerular filtration rate (gfr) of less than 20 ml per 1.73 m2 of body-surface area. 5. type 1 diabetes mellitus. 6. dyspnea is primarily due to non-cardiac causes. 7. cardiogenic shock. 8. acute coronary syndrome within 30 days prior to randomization. 9. planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization. 10. signs of ketoacidosis and/or hyperosmolar hyperglycemic syndrome (ph\>7.30 and glucose \>15 mmol/l and hco3\>18 mmol/l). 11. pregnant or nursing (lactating) women.
acute exposure to high altitude on pulmonary artery pressure and right heart function (echo)

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary hypertension (pah, cteph) to assess the acute response to high altitude ("säntis"; 2500m above sea level) on pulmonary artery pressure and right heart function (echo)

low altitude baseline measurements will be performed in zurich (460m asl) including echocardiography, right heart catheterization, six-minute walk test (6mwt), pulmonary function test, clinical assessment and blood gas analysis. randomly assigned to the order of testing, the participants will be tested in low altitude (zurich, 470m) and at high altitude (2500m). several times within the exposure, the pulmonary artery pressure (pap) and the right heart function will be assessed by echo.

Eligibility criteria:
inclusion criteria: * informed consent * ph diagnosed according to internation guidelines: mean pulmonary artery pressure (mpap) ≥ 25 mmhg along with a pulmonary artery wedge pressure (pawp) ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting partial oxygen pressure (pao2) ≤7.3 kpa corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kilopascal (kpa)) * susceptibility to high altitude related diseases (ams, high-altitude pulmonary edema (hape), etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: high altitude pulmonary artery pressure echocardiography right heart function
validation of existing diabetes risk models in a swedish population

Conditions: Type2diabetes

Summary: the goal of this observational study is to validate existing non-invasive diabetes clinical prediction models in a swedish population. the main question it aims to answer is: how well 11 existing models will perform in predicting incident type 2 diabetes in participants from the västerbotten intervention programme (vip). participants in vip are residents of västerbotten that are invited for a comprehensive health screening at 30- (until 1995), 40-, 50-, and 60-years of age.

several type 2 diabetes risk prediction models have been developed but how it will perform in a swedish population is not known. no diabetes risk prediction model is routinely used in sweden. the aim of this study is therefore, to validate 11 non-invasive models and to evaluate the performance to predict incident type 2 diabetes in a swedish population. a population-based cohort from the västerbotten intervention programme (vip) from 1990 to 2020 will be the validation sample. incident type 2 diabetes within 10-years of follow-up, will be determined by oral glucose tolerance test or through self-reports. a self-administered questionnaire is completed, and anthropometric, clinical, and biochemical measures are obtained at each of the health screening visits. in the statistical analysis the overall performance of the models will be compared using the brier score. in addition. discrimination and calibration of all the models will be evaluated. recalibration of models will be done.

Eligibility criteria:
inclusion criteria: • at least one visit within the västerbotten intervention program exclusion criteria: • prevalent diabetes at first visit defined by a fasting capillary plasma glucose \>7mmol/l, a 2-hour capillary plasma glucose of ≥12.2 mmol/l or self-reported history of diabetes

Keywords: non-invasive prediction model incident diabetes validation
optimizing pain control in transurethral resection of the prostate

Conditions: Pain; BPH With Urinary Obstruction; BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

Summary: the purpose of this study is to develop a multi-modal protocol for pain management after turp that minimizes opioid use. the investigators hypothesize this approach will provide non-inferior pain control to the current standard of care which includes opioids as the primary agent. the investigators believe this is an important step in reducing the opioid epidemic in surgical patients.

in our study, the investigators will randomize turp patients to standard of care versus a multi-modal protocol. multi-modal pain control is defined as: "analgesia that combines 2 or more agents that act by different mechanisms to provide analgesia with better pain relief and less opioids". in addition, patients in the intervention arm will receive education regarding pain control and opioid use. the investigators aim to demonstrate non-inferior pain control with this approach. the investigators hope this will inform new guidelines for pain control after turp, minimize opioid use in this patient population, and educate physicians and patients on providing excellent pain control while minimizing the risks of opioid use. the investigators believe this could ultimately serve as a model for other endoscopic urologic procedures as well.

Eligibility criteria:
inclusion criteria: * are identified as candidates for turp * are 18 years of age or greater * are proficient in english exclusion criteria: * have filled an opioid prescription in the last 2 months * have an allergy to a medication included in the protocol * have a history of pelvic radiation * have renal failure (serum cr \> 2.0 mg/dl), peptic ulcer disease, history of gastric bypass, cirrhosis, or other contraindication precluding use of nsaid's * have liver failure, hepatitis, or alcohol abuse which precludes use of acetaminophen

Keywords: postoperative pain transurethral resection of the prostate multimodal pain control
a study of the safety and tolerability of incb050465 in pemphigus vulgaris

Conditions: Pemphigus Vulgaris

Summary: the purpose of this study is to assess the safety and tolerability of parsaclisib in participants with mild to moderate pemphigus vulgaris.


Eligibility criteria:
inclusion criteria: * clinically documented and confirmed diagnosis of pemphigus vulgaris: minimum of 6 months of pemphigus vulgaris diagnosis; positive for anti-desmoglein (dsg)1 or dsg3; pemphigus disease area index score of 8 to 45 points; active skin, scalp, or mucosal lesions. * disease progression after treatment with standard therapies that are known to confer clinical benefit, or intolerant to treatment; there is no limit to the number of prior treatment regimens. * willingness to avoid pregnancy or fathering children. * if required, willing to receive pneumocystis jirovecii pneumonia prophylaxis during the study period. exclusion criteria: * pregnant or breast-feeding female. * participants with pemphigus vulgaris who are treatment-naive. * use of protocol-specified medications within defined periods before baseline. * evidence or history of clinically significant infection or protocol-defined medical conditions * laboratory values outside the protocol-defined range at screening. * known or suspected allergy to parsaclisib or any component of the study drug. * known history of clinically significant drug or alcohol abuse in the last year before baseline. * inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator. * any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Keywords: pemphigus vulgaris phosphatidylinositol 3-kinase delta immunoglobulin g autoantibodies
ai-hope lung cancer: building a predictive tool for metastatic lung cancer

Conditions: NSCLC Stage IV

Summary: the goal of our project is building a predictive response algorithm for patients with metastatic lung cancer, exploiting an artificial intelligence platform. it will collect patient information from all areas (clinical, laboratory, radiological, pathological) and analyse them, understanding connections and correlations, both at baseline and at pre-specified timepoints. it would lead to the development of a reliable and constantly evolving predictive score, able to continuously re-weight the importance of each variable as new data come in. since the greatest clinical need is identifying non-responders to immunotherapy and chemo-immunotherapy combination (30% of all treated patients), these two populations are defined as the starting cohorts (cohort a, immunotherapy alone, cohort b, chemo-immunotherapy combinations). for each cohort, three main questions are to be answered: q1) early progressors (defined as progressive disease or death within three months of treatment or at first radiological restaging) q2) toxicity (with a special focus on severe toxicities g≥3) q3) long survivors (defined as patients reaching an overall survival of at least 1.5x median overall survival in registrative trials) the early identification of non-responders, high-risk patients (or on the other hand, long survivors) would help their healthcare planning, providing individualised follow-up strategies or prompting their inclusion in alternative treatments (eg clinical trials). for all cohorts, first data entry will be retrospective and second data entry will be prospective (as validation set).


Eligibility criteria:
inclusion criteria: * patients with histological or cytological diagnosis of nsclc * stage iv according to investigator's staging procedures (or any locally advanced tumour not feasible for local radical treatment) * treatment with at least 1 cycle of mono-immunotherapy or chemo-immunotherapy (as per clinical practice) * availability of follow-up exclusion criteria: * patients with other thoracic tumours non-nsclc (i.e. sclc) * stage other than iv or feasible for radical treatment upfront * treatment within clinical trials (with combination regimens different from the aforementioned combinations) * lost to follow-up
health effects of biodiesel exhaust exposure

Conditions: Vascular Endothelium

Summary: urban air pollution is a major contributor to greenhouse gases and has been shown to increase cardiovascular mortality and morbidity. this century has seen a rebirth of biofuel marketing and research, with biodiesel emerging as one of the strongest contenders within international markets. the pursuit of alternative renewable fuels is incredibly complex and has powered research in agriculture, biotechnology, production, transportation, feedstocks, ecology and biomass manufacturing. in spite of this, health effects have been an almost completely overlooked aspect. the purpose of this study is to investigate whether 100% biodiesel exhaust exposure in healthy volunteers leads to cardiovascular and inflammatory responses. further investigations into the chemical composition of biodiesel exhaust will also be performed.


Eligibility criteria:
inclusion criteria: non-smoking, healthy male subjects. all subjects undergo a general health examination and are required to have normal clinical examination, ecg, blood tests and lung function. exclusion criteria: * diabetes mellitus * cardiovascular disease * asthma * respiratory infection within 2 weeks of the study * antioxidant- and/or vitamin supplementation within 1 week prior to, as well as during the course of the study. (incl vitamin c, acetylcysteine) * smokers or regular snus usage

Keywords: air pollution biodiesel exhaust diesel exhaust vascular function fibrinolysis acute endothelial responses
evaluation of long-term gait development in infants with neonatal encephalopathy using infant treadmill

Conditions: Hypoxic-Ischemic Encephalopathy; Periventricular Leukomalacia; Intraventricular Hemorrhage Neonatal; Bilirubin Encephalopathy; Kernicterus; Hypoglycemia, Neonatal; Cerebral Infarction

Summary: there have been many studies on the use of running training in older children to improve gait development in children with cerebral palsy. the aim of our study was to conduct early treadmill training in infants who were highly suspected of cerebral palsy and to follow up on their long-term gait development.


Eligibility criteria:
inclusion criteria: 1. gestational age \< 33w; 2. correction of gestational age \< 3 months; 3. it has been diagnosed as hypoxic-ischemic encephalopathy, periventricular intraventricular hemorrhage, periventricular leukomalacia, bilirubin encephalopathy, persistent hypoglycemia and cerebral infarction. 4. there was no other therapeutic intervention before entering the study; 5. informed consent is signed by the family. exclusion criteria: 1. brain injury caused by central or peripheral infection (cerebrospinal fluid positive / torch test positive / three major conventional culture positive); 2. brain damage caused by convulsion; 3. metabolic brain damage caused by genetic defects; 4. suffering from known severe congenital malformations; 5. definite head trauma during labor or postpartum; 6. peripheral neuromuscular disease or abnormal skeletal system.

Keywords: treadmill infants neonatal encephalopathy neonatal brain injury
the synbiotics effects in polycystic ovary syndrome: a randomized controlled trial

Conditions: PCOS- Polycystic Ovary Syndrome

Summary: the goal of this clinical trial is to compare the effect of synbiotics and placebo in thai women with polycystic ovary syndrome. the main questions it aims to answer are: * do synbiotics have a positive effect on the gut microbiome? * do synbiotics have a positive effect on reproductive outcomes? * do synbiotics have a positive effect on cardiovascular outcomes? participants will be randomized, and blinded to receive either synbiotics or placebo. while placebo is a comparison group: researchers will compare with placebo to see if the effects on reproductive and cardiovascular risk differ.

analysis of gut microbiome in thai women with polycystic ovary syndrome and the synbiotics effect on reproductive and cardiovascular risk: a randomized controlled trial

Eligibility criteria:
inclusion criteria: - pcos exclusion criteria: * atb use
improved patient recovery after anesthesia with hypercapnia hyperpnoea

Conditions: Hypercapnia

Summary: the proposed study will measure the time from the end of surgery until the time patients meet the discharge criteria from the postoperative anesthesia care unit and the time from the end of surgery until the patients regained cognitive function after anesthesia.

hypercapnia has been used in conjunction with hyperpnoea to provide a more rapid return of responsiveness after inhaled anesthesia. in our first clinical study with isoflurane we confirmed that the time from turning off the vaporizer to opening of eyes was shortened by an average of 62% when the minute ventilation was elevated and the end tidal carbon dioxide concentration was kept at 52 mmhg rather than 28 mmhg during emergence. in our second study we found that hypercapnia and hyperpnoea accelerated recovery proportionately for sevoflurane and desflurane. the benefits of accelerating subject recovery in the operating room may extend to the entire recovery period if the subject is more alert and easier to care for when they arrive in the post anesthesia care unit.

Eligibility criteria:
inclusion criteria: * adults * asa class i-iii * both genders * scheduled to undergo eye surgery at the moran hospital. exclusion criteria: * a history of renal or hepatic disease, * chronic alcohol or drug abuse, * disabling neuropsychiatric disorder, * hypersensitivity or unusual response to other halogenated anesthetics, * pulmonary hypertension, * increased intracranial pressure, * seizure disorder * personal/familial history of malignant hyperthermia. * currently being treated with known hepatic enzyme-inducing drugs (e.g., phenobarbital, dilantin or isoniazid) * or with drugs known to alter anesthetic requirements (e.g., opiates, clonidine, alpha2 agonists, alcohol, anticonvulsants, antidepressants, barbiturates, benzodiazepines or other tranquilizers). * intolerance to non-steroidal anti-inflammatories. * have received general anesthesia within the previous 7 days, * received any investigational drug within the previous 28 days, * participated in a previous isoflurane or desflurane study * female subjects can be neither pregnant nor breast feeding.

Keywords: hypercapnia hyperpnoea accelerated recovery
a study of ono-7018 in patients with relapsed or refractory non-hodgkin lymphoma

Conditions: Non Hodgkin Lymphoma

Summary: ono-7018 is a selective inhibitor of mucosa associated lymphoid tissue protein 1 (malt1) and is expected to exhibit antitumor activity in nhl. this study is phase1 study to evaluate the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (biomarkers) and efficacy of ono-7018 in patients with relapsed or refractory nhl.


Eligibility criteria:
inclusion criteria: 1. patient with histologically/cytologically confirmed diagnosis of any of the subtypes of b-cell nhl or t-cell nhl defined below as documented by medical records and with histology based on criteria established by the world health organization (swerdlow 2017) 2. relapsed or refractory patient who is refractory or intolerant to standard therapy or for whom, in the opinion of the investigator, there is no appropriate treatment for the primary disease. 3. patient who has measurable disease 4. eastern cooperative oncology group performance status 0 to 2 5. life expectancy of at least 3 months exclusion criteria: 1. any serious or uncontrolled medical disorder that may increase the risk associated with study participation or study treatment, or interfere with the interpretation of study results 2. patient with malignancies other than lymphoid malignancy allowed per inclusion criteria 3. prior treatment with a malt1 inhibitor 4. patient is unable to swallow tablets
computed tomography-guided brachytherapy plus chemotherapy for locally recurrent rectum cancer

Conditions: Rectum Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of ct guided 125i seeds implant plus systemic chemotherapy for locally recurrent rectum cancer.

the primary aim of this study is to determined the safety and efficacy of ct guided 125i seeds implant plus systemic chemotherapy for locally recurrent rectum cancer.the patients with recurrence in pelvic or on pelvic wall after rectal resection were treated with 125i seeds implant plus chemotherapy or chemotherapy alone. the side-effect, tumor response and survival data were recorded.

Eligibility criteria:
inclusion criteria: * limited locoregional recurrence including solitary recurrence at primary tumor bed, solitary intraabdominal peritoneal recurrence, and single regional lymph node recurrence (no more than 3 lymph nodes) based on diagnosis by ct, and confirmed by percutaneous puncture biopsy * second-line treatment for advanced colorectal cancer,irinotecan was not previously used. * age range 18-70 years old * ecog performance status 0-1 * life expectancy of more than 3 months * adequate organ function exclusion criteria: previous serious cardiac disease * history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * pregnant or lactating women * chronic inflammatory bowel disease or intestinal obstruction * serious uncontrolled diseases and intercurrent infection
cxcr4-targeted pet/ct imaging in hematological malignancies

Conditions: CXCR4; PET/CT; Hematological Malignancy

Summary: the incidence and mortality of hematological malignancies remain high. although 18f-fdg pet/ct imaging is the most common molecular imaging technique used in clinic, the non-specific uptake of 18f-fdg leads to the problems of false negative or positive in hematological malignancies, which makes it difficult to diagnose and evaluate the efficacy. cxcr4 (c-x-c chemokine receptor type 4) is overexpressed in various hematological malignancies, and is associated with poor prognosis. cxcr4-targeted molecular imaging, such as 68ga-pentixafor pet/ct imaging, has an important potential in hematological malignancies. therefore, this study will evaluate the efficacy of cxcr4-targeted pet/ct imaging for diagnosis and staging of hematological malignancies, compared with 18f-fdg pet/ct imaging.


Eligibility criteria:
inclusion criteria: 1. volunteer to participate and sign an informed consent form; 2. 18 ≤ age ≤ 90 years; 3. patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies; 4. willing and able to follow schedule visits, treatment plans and laboratory tests. exclusion criteria: 1. pregnancy or breastfeeding; 2. allergic to cxcr4-targeted tracers or excipients; 3. fasting blood glucose level exceeded 11.0 mmol/l prior to injection of 18f-fdg; 4. those who cannot complete pet/ct scan, including inability to keep supine, claustrophobia, radiation phobia, etc.; 5. researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.